PD-1 inhibition in sarcoma still needs investigation – Authors’ reply

Hussein A. Tawbi; Vanessa Bolejack; Melissa Burgess; Scott Schuetze

doi:10.1016/S1470-2045(17)30922-1

PD-1 inhibition in sarcoma still needs investigation – Authors’ reply

Hussein A. Tawbi, Vanessa Bolejack, Melissa Burgess, Scott Schuetze

Melanoma Medical Oncology

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	e7
Journal	The lancet oncology
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/S1470-2045(17)30922-1
State	Published - Jan 2018

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(17)30922-1

Cite this

@article{d404e220af214af0ade01f0f6aefcab9,

title = "PD-1 inhibition in sarcoma still needs investigation – Authors{\textquoteright} reply",

author = "Tawbi, {Hussein A.} and Vanessa Bolejack and Melissa Burgess and Scott Schuetze",

note = "Funding Information: HAT reports Bristol-Myers Squibb consulting and research support to his institution and consulting for Novartis and EMD-Serono, outside the submitted work. MB reports personal fees from Immune Design, EMD Serono, and Eisai, and other from Eli Lilly, outside the submitted work. SS reports grants from SARC and non-financial support from Merck, during the conduct of the study, and personal fees from Janssen and Daiichi Sankyo, outside the submitted work. VB declares no competing interests.",

year = "2018",

month = jan,

doi = "10.1016/S1470-2045(17)30922-1",

language = "English (US)",

volume = "19",

pages = "e7",

journal = "The lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - PD-1 inhibition in sarcoma still needs investigation – Authors’ reply

AU - Tawbi, Hussein A.

AU - Bolejack, Vanessa

AU - Burgess, Melissa

AU - Schuetze, Scott

N1 - Funding Information: HAT reports Bristol-Myers Squibb consulting and research support to his institution and consulting for Novartis and EMD-Serono, outside the submitted work. MB reports personal fees from Immune Design, EMD Serono, and Eisai, and other from Eli Lilly, outside the submitted work. SS reports grants from SARC and non-financial support from Merck, during the conduct of the study, and personal fees from Janssen and Daiichi Sankyo, outside the submitted work. VB declares no competing interests.

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85039727844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039727844&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(17)30922-1

DO - 10.1016/S1470-2045(17)30922-1

M3 - Letter

C2 - 29304367

AN - SCOPUS:85039727844

SN - 1470-2045

VL - 19

SP - e7

JO - The lancet oncology

JF - The lancet oncology

IS - 1

ER -

PD-1 inhibition in sarcoma still needs investigation – Authors’ reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this